Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Exelixis Inc EXEL

Healthcare Biotechnology
Exelixis, Inc. is an oncology company. The Company is engaged in developing medicines and combination regimens at the forefront of cancer care. It has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma (RCC), for previously treated hepatocellular carcinoma (HCC) and for previously treated, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC), and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer (MTC). The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) approved the treatment of hypertension.


NDAQ:EXEL - Post by User

Exelixis Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(200)
•••
Post by whytestockson Oct 30, 2024 11:47am
11 Views
Post# 36288834

EXEL Price Target Alert: $38.00. Issued by Truist Financial

EXEL Price Target Alert: $38.00. Issued by Truist Financial
Breaking News: $EXEL EXEL Price Target Alert: $38.00. Issued by Truist Financial2024-10-30 08:59:46 ET Asthika Goonewardene from Truist Financial issued a price target of $38.00 for EXEL on 2024-10-30 07:59:00. The adjusted price target was set to $38.00. At the time of the announcement, EXEL was trading at $28.73. The overall price target consensus...EXEL - EXEL Price Target Alert: $38.00. Issued by Truist Financial

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities